ELI LILLY AND COMPANY |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 777.1 USD | +5.42% |
|
+4.20% | +33.29% |
| 08:49pm | Wall Street stocks fall as markets weigh strong wage data, Fed meeting | RE |
| 08:36pm | Trending : Eli Lilly Reports Strong Sales of Weight-Loss, Diabetes Drugs | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
06:25am
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
737.2
USD
Average target price
813.3
USD
Spread / Average Target
+10.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +33.29% | 664B | |
| +29.29% | 567B | |
| -7.48% | 354B | |
| +18.67% | 330B | |
| +4.55% | 286B | |
| +13.79% | 234B | |
| +4.93% | 199B | |
| -9.78% | 196B | |
| -4.86% | 148B | |
| -11.02% | 145B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech
